Health ❯ Pharmaceuticals

Weight Loss Drugs

Ozempic Semaglutide Wegovy GLP-1 Receptor Agonists GLP-1 Drugs GLP-1 Agonists GLP-1 Clinical Trials Tirzepatide Mounjaro Ozempic and Wegovy GLP-1 Medications Eli Lilly Novo Nordisk Market Impact Market Competition Zepbound Side Effects Safety Concerns Diabetes Treatment Market Growth Supply Issues Weight Regain Study Results Popularity GLP-1 Agonist Drugs GLP1s Drug Efficacy Viking Therapeutics Amgen Chronic Weight Management FDA Approval Heart Attack Prevention Pricing Pricing Issues Partnerships Misuse GLP-1s Amycretin Regulation Addiction Treatment Orlistat Counterfeit Medications Novo Nordisk Products Counterfeit Products Semaglutides Copycat Medications Type 2 Diabetes Competition Danuglipron Oral Medications

Pfizer Clinches $10 Billion Metsera Deal to Rebuild Obesity Pipeline

Metsera's board rejected Novo Nordisk's rival bid over legal concerns, clearing the way for a shareholder vote.

Brooks Nader Calls Her Ongoing GLP‑1 Use a 'Crutch'